Deal Note: Crowell & Moring Client Integrated BioTherapeutics Enters Into Exclusive Agreement with Chembio Diagnostics to Develop POC Diagnostic Tests for Ebola
Firm News | less than 1 min read | 10.27.14
Washington, D.C. – October 27, 2014: Crowell & Moring, LLP is representing Integrated BioTherapeutics, Inc. (IBT), a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases, as it enters into an exclusive agreement with Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases. Under the terms of the agreement, Chembio will combine its patented DPP technology with IBT's proprietary Ebola reagents to develop POC diagnostic tests for Ebola and febrile illness. Chembio will have exclusive rights to any POC product developed through this agreement. Financial terms of the agreement were not disclosed.
Insights
Firm News | 11 min read | 06.05.25
Crowell Attains Leading Rankings in Chambers USA 2025
Washington – June 5, 2025: Crowell & Moring earned 80 rankings for 71 lawyers, as well as 43 national and statewide practice area rankings, in the Chambers USA 2025 guide. The rankings are driven by independent interviews of clients and lawyers at peer firms.
Firm News | 1 min read | 06.05.25
Firm News | 2 min read | 06.04.25
Crowell & Moring Advises Quantinuum on $1 Billion Joint Venture with Qatar’s Al Rabban Capital
Firm News | 6 min read | 06.03.25